NCT05550415View on ClinicalTrials.gov

The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

August 31, 2025

Conditions
Triple Negative Breast CancerChemotherapy EffectSimvastatin Adverse Reaction
Interventions
DRUG

Simvastatin 40mg

The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy

DRUG

Placebo

The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy

Trial Locations (1)

10430

RECRUITING

Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta Pusat

All Listed Sponsors
lead

Indonesia University

OTHER